3 Profitable Stocks We Think Twice About

via StockStory
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

PAYX Cover Image

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here are three profitable companies to avoid and some better opportunities instead.

Paychex (PAYX)

Trailing 12-Month GAAP Operating Margin: 38.6%

Once known as the go-to service for small business payroll needs, Paychex (NASDAQ:PAYX) provides payroll processing, HR services, employee benefits administration, and insurance solutions to small and medium-sized businesses.

Why Does PAYX Worry Us?

  1. Sales trends were unexciting over the last five years as its 9.9% annual growth was well below the typical software company
  2. Estimated sales growth of 5.4% for the next 12 months implies demand will slow from its two-year trend
  3. Efficiency has decreased over the last year as its operating margin fell by 1.1 percentage points

Paychex’s stock price of $122.80 implies a valuation ratio of 6.2x forward price-to-sales. Dive into our free research report to see why there are better opportunities than PAYX.

PACCAR (PCAR)

Trailing 12-Month GAAP Operating Margin: 8.3%

Founded more than a century ago, PACCAR (NASDAQ:PCAR) designs and manufactures commercial trucks of various weights and sizes for the commercial trucking industry.

Why Are We Wary of PCAR?

  1. Products and services are facing significant end-market challenges during this cycle as sales have declined by 11.2% annually over the last two years
  2. Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
  3. Diminishing returns on capital suggest its earlier profit pools are drying up

At $135.30 per share, PACCAR trades at 21.8x forward P/E. If you’re considering PCAR for your portfolio, see our FREE research report to learn more.

CDW (CDW)

Trailing 12-Month GAAP Operating Margin: 7.3%

Serving as a crucial bridge between technology manufacturers and end users since 1984, CDW (NASDAQ:CDW) is a multi-brand provider of information technology solutions that helps businesses and public sector organizations select, implement, and manage hardware, software, and IT services.

Why Do We Think Twice About CDW?

  1. Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 3.9% over the last five years was below our standards for the business services sector
  2. Estimated sales growth of 3% for the next 12 months is soft and implies weaker demand
  3. Annual earnings per share growth of 2% underperformed its revenue over the last two years, showing its incremental sales were less profitable

CDW is trading at $147.93 per share, or 13.1x forward P/E. Read our free research report to see why you should think twice about including CDW in your portfolio.

Stocks We Like More

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article